Related Experiment Video
Updated: Jun 10, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models
Sarah Willis1, James Stoll, Lawrence Sweetman
1Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 Coulter, Amarillo, TX 79106, USA.
Abstract:
We hypothesized that in epileptic brains citric acid cycle intermediate levels may be deficient leading to hyperexcitability. Anaplerosis is the metabolic refilling of deficient metabolites. Our goal was to determine the anticonvulsant effects of feeding triheptanoin, the triglyceride of anaplerotic heptanoate. CF1 mice were fed 0-35% calories from triheptanoin. Body weights and dietary intake were similar in mice fed triheptanoin vs. standard diet. Triheptanoin feeding increased blood propionyl-carnitine levels, signifying its metabolism. 35%, but not 20%, triheptanoin delayed development of corneal kindled seizures. After pilocarpine-induced status epilepticus (SE), triheptanoin feeding increased the pentylenetetrazole tonic seizure threshold during the chronically epileptic stage. Mice in the chronically epileptic stage showed various changes in brain metabolite levels, including a reduction in malate. Triheptanoin feeding largely restored a reduction in propionyl-CoA levels and increased methylmalonyl-CoA levels in SE mice. In summary, triheptanoin was anticonvulsant in two chronic mouse models and increased levels of anaplerotic precursor metabolites in epileptic mouse brains. The mechanisms of triheptanoin's effects and its efficacy in humans suffering from epilepsy remain to be determined.
Insights
Triheptanoin, a triglyceride, demonstrated anticonvulsant effects in mouse models of epilepsy by restoring brain metabolite levels. Further research is needed to determine its efficacy in humans.
Area of Science:
- Biochemistry
- Neuroscience
- Metabolic Disorders
Background:
- Epileptic brains may exhibit deficiencies in citric acid cycle intermediates, potentially leading to hyperexcitability.
- Anaplerosis is a metabolic process crucial for replenishing deficient metabolites.
- Understanding metabolic alterations in epilepsy is key to developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the anticonvulsant properties of triheptanoin, a triglyceride of heptanoate, in mouse models of epilepsy.
- To assess the impact of triheptanoin supplementation on brain metabolite levels associated with the citric acid cycle.
- To determine if triheptanoin can mitigate seizure activity and hyperexcitability in epilepsy models.
Main Methods:
- Mice (CF1) were fed varying percentages of calories from triheptanoin.
- Seizure susceptibility was evaluated using corneal kindling and pentylenetetrazole (PTZ) threshold tests after pilocarpine-induced status epilepticus (SE).
- Blood and brain metabolite levels, including propionyl-carnitine, propionyl-CoA, and methylmalonyl-CoA, were analyzed.
Main Results:
- Triheptanoin feeding increased blood propionyl-carnitine levels, indicating successful metabolism.
- 35% triheptanoin supplementation delayed the development of kindled seizures and increased the PTZ seizure threshold in chronically epileptic mice.
- Triheptanoin administration partially restored reduced propionyl-CoA levels and increased methylmalonyl-CoA in the brains of SE mice.
Conclusions:
- Triheptanoin exhibits anticonvulsant effects in established mouse models of chronic epilepsy.
- The study suggests that triheptanoin can modulate key anaplerotic metabolites in the epileptic brain.
- Further investigation is warranted to elucidate the precise mechanisms and evaluate triheptanoin's therapeutic potential in human epilepsy.
